

Appl. No. 10/526,822
Reply to Office Action of September 12, 2007

RECEIVED
CENTRAL FAX CENTER

OCT 16 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A clear ophthalmic solution comprising latanoprost having a concentration of 0.005 to 0.01% (W/V) as an active ingredient and benzalkonium chloride as a preservative wherein white turbidity due to a change of formulation is prevented by at least one means selected from the following 1) to [[3]]2);

~~1) adding polyoxyethylene hydrogenated castor oil 60 or polyoxyl 35-caster oil,~~

[[2]]1) using benzalkonium chloride represented by the formula of $[C_6H_5CH_2N(CH_3)_2R]Cl$ (wherein R is alkyl having 12 carbon atoms) as the preservative and

[[3]]2) adding a tonicity agent consisting essentially of a nonionic tonicity agent.

Appl. No. 10/526,822
Reply to Office Action of September 12, 2007

2. **(Previously presented)** The ophthalmic solution as claimed in claim 1, wherein the benzalkonium chloride is used and its concentration is 0.003 to 0.01% (WV).

3. **(Cancelled)**.

4. **(Previously presented)** The ophthalmic solution as claimed in claim 9, wherein the nonionic tonicity agent is used and is selected from the group consisting of glycerin, mannitol, polyethylene glycol, propylene glycol, trehalose or sucrose.

5. **(Currently amended)** A method of preventing white turbidity due to a change of formulation in an ophthalmic solution comprising latanoprost having a concentration of 0.005 to 0.01% (W/V) as an active ingredient and benzalkonium chloride as a preservative by at least one means selected from the following 1) to ~~[[3]]2~~):
~~1) adding polyoxyethylene hydrogenated easter oil 60 or polyoxyl 35 easter oil;~~

Appl. No. 10/526,822
Reply to Office Action of September 12, 2007

[[2]]1) using benzalkonium chloride represented by the formula of $[C_6H_5CH_2N(CH_3)_2R] Cl$ (wherein R is alkyl having 12 carbon atoms) as the preservative and

[[3]]2) adding a tonicity agent consisting essentially of a nonionic tonicity agent.

6. **(Previously presented)** The method of preventing white turbidity as claimed in claim 5, wherein benzalkonium chloride is used and its concentration is 0.003 to 0.01% (W/V).

7. **(Cancelled)**.

8. **(Previously presented)** The method of preventing white turbidity as claimed in claim 10, wherein the nonionic tonicity agent is used and is selected from the group consisting of glycerin, mannitol, polyethylene glycol, propylene glycol, trehalose or sucrose.

9. **(Original)** The ophthalmic solution as claimed in claim 2, wherein a latanoprost concentration is 0.005% (W/V).

Appl. No. 10/526,822
Reply to Office Action of September 12, 2007

10. (Original) The method of preventing white turbidity as claimed in claim 6, wherein a latanoprost concentration is 0.005% (W/V).